2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

H4 cells

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144315
    Snail/HDAC-IN-1

    		HDAC Cancer
    Snail/HDAC-IN-1 is a potent Snail/HDAC dual target inhibitor. Snail/HDAC-IN-1 displays potent inhibitory activity against HDAC1 with an IC50 of 0.405 μM and potent inhibition against Snail with a Kd of 0.18 μM. Snail/HDAC-IN-1 increases histone H4 acetylation in HCT-116 cells and decreases the expression of Snail protein to induce cell apoptosis .
    Snail/HDAC-IN-1
  • HY-101189
    JNJ-39758979

    		Histamine Receptor Neurological Disease Endocrinology
    JNJ-39758979 is a selective, orally active, and high-affinity histamine H4 receptor antagonist with Kis of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H4 receptor, respectively. JNJ-39758979 functionally antagonizes histamine-induced cAMP inhibition with a pA2 of 7.9 in transfected cells. JNJ-39758979 shows good anti-inflammatory and antipruritic activity .
    JNJ-39758979
  • HY-146131
    ATG7-IN-3

    		Atg7 Atg8/LC3 Autophagy Cancer
    ATG7-IN-3 (compound 18) is a potent ATG7 inhibitor, with an IC50 of 0.048 μM. ATG7-IN-3 inhibits autophagy. ATG7-IN-3 inhibits the formation of endogenous LC3B puncta in the neuroglioma cell line H4 .
    ATG7-IN-3
  • HY-123532
    JNJ10191584

    VUF6002

    		 Histamine Receptor Neurological Disease
    JNJ10191584 (VUF6002) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 shows 540-fold selectivity to H4 receptor over H3 receptor with a Ki value of 14.1 μM. JNJ10191584 inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively .
    JNJ10191584
  • HY-107558
    JNJ10191584 maleate

    VUF6002 maleate

    		 Histamine Receptor Neurological Disease
    JNJ10191584 (VUF6002) maleate (compound 40) is an orally active and selective histamine H4 receptor antagonist with a Ki value of 26 nM. JNJ10191584 maleate shows 540-fold selectivity to H4 receptor over the H3 receptor with a Ki value of 14.1 μM. JNJ10191584 maleate inhibits chemotaxis of eosinophils and mast cells with IC50 values of 530 nM and 138 nM, respectively .
    JNJ10191584 maleate
  • HY-101189B
    JNJ-39758979 dihydrochloride

    		Histamine Receptor Inflammation/Immunology
    JNJ-39758979 dihydrochloride is a selective, orally active, and high-affinity histamine H4 receptor antagonist, with Kis of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H4 receptor, respectively. JNJ-39758979 dihydrochloride functionally antagonizes histamine-induced cAMP inhibition with a pA2 of 7.9 in transfected cells. JNJ-39758979 dihydrochloride shows good anti-inflammatory and antipruritic activity .
    JNJ-39758979 dihydrochloride
  • HY-101063
    Amthamine dihydrobromide

    Amthamine is a histamine receptor (H1R-H4R) agonist. Amthamine can produce liver congestion and necrosis of liver cells. Amthamine can be used to study the induction effect of H1R-H4 agonist on hepatotoxicity .
    Amthamine dihydrobromide
  • HY-N12323
    6′-Galactosyllactose

    		Others Inflammation/Immunology
    6′-Galactosyllactose is the main oligosaccharide that makes up galactose, a component of human milk. 6′-Galactosyllactose can synthesize human milk oligosaccharides and synthetic galactosyllactose with 3′-Galactosyllactose and 4′-Galactosyllactose, and reduce inflammation in human T84, NCM-460 and H4 cells and intestinal tissues .
    6′-Galactosyllactose
  • HY-162060
    YPX-C-05

    		HDAC Cardiovascular Disease
    YPX-C-05 is a hydroxamic acid-based HDAC inhibitor. YPX-C-05 exerts significant vasodilatory effects. YPX-C-05 exhibits inhibitory effects on HDACs and increases histone H4 acetylation in endothelial cells. YPX-C-05 can be used for hypertension research .
    YPX-C-05
  • HY-17039
    Alcaftadine

    R89674

    		 Histamine Receptor Inflammation/Immunology Endocrinology
    Alcaftadine (R89674) is a histamine H1 receptor antagonist, which is used to prevent eye irritation brought on by allergic conjunctivitis. Alcaftadine is a broad-spectrum antihistamine displaying a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors. Alcaftadine also exhibits modulatory action on immune cell recruitment and mast cell stabilizing effects .
    Alcaftadine
  • HY-13508
    JNJ-7777120

    		Histamine Receptor Inflammation/Immunology
    JNJ-7777120 is a potent and selective histamine H4 receptor antagonist (Ki=4.5 nM). JNJ-7777120 effectively blocks histamine-induced migration of mouse tracheal mast cells from connective tissue to epithelial cells. JNJ-7777120 also significantly blocks neutrophil infiltration in a mouse Zymosan-induced peritonitis model. JNJ-7777120 has a good potential to study antipruritic and anti-inflammatory .
    JNJ-7777120
  • HY-125236
    BET-IN-19

    		Epigenetic Reader Domain Cancer
    BET-IN-19 (Compound 146) is a BET inhibitor. BET-IN-19 inhibits hlL-6 mRNA transcription (IC50 ≤ 0.3 uM), and c-myc activity in human AML MV4-11 cell (IC50 ≤ 0.3 uM)。BET-IN-19 inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC50 ≤ 0.3 uM) .
    BET-IN-19
  • HY-13265
    AR-42
    2 Publications Verification

    HDAC-42; OSU-HDAC42

    		 HDAC Autophagy Apoptosis Cancer
    AR-42 (HDAC-42; OSU-HDAC42) is a potent, orally bioavailable pan-HDAC inhibitor (IC50=16 nM). AR-42 induces growth inhibition, cell-cycle arrest, apoptosis, and activation of caspases-3/7. AR-42 promotes hyperacetylation of H3, H4, and alpha-tubulin, and up-regulation of p21. AR-42 shows cytotoxicity against various human cancer cell lines .
    AR-42
  • HY-156091
    PI3Kα/HDAC6-IN-1

    		PI3K HDAC Cancer
    PI3Kα/HDAC6-IN-1 (compound 21j) is a dual PI3Kα/HDAC6 inhibitor with IC50 of 2.9 and 26 nM, respectively. PI3Kα/HDAC6-IN-1 also inhibits AKT(Ser473) phosphorylation and induces the accumulation of acetylated α-tubulin without affecting acetylated histones H3 and H4. PI3Kα/HDAC6-IN-1 efficiently inhibits L-363 cell line (IC50=0.17 μM) and has good anti-cancer activity .
    PI3Kα/HDAC6-IN-1
  • HY-152552
    α-Synuclein inhibitor 8

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 8 is an active inhibitor of α-Synuclein with an IC50 value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .
    α-Synuclein inhibitor 8
  • HY-146130
    ATG7-IN-2

    		Atg7 Autophagy Cancer
    ATG7-IN-2 (compound 1) is a potent ATG7 inhibitor, with an IC50 of 0.089 μM. ATG7-IN-2 inhibits autophagy marker LC3B .
    ATG7-IN-2
  • HY-P2228
    Chlamydocin

    		HDAC Apoptosis Cancer
    Chlamydocin, a fungal metabolite, is a highly potent HDAC inhibitor, with an IC50 of 1.3 nM. Chlamydocin exhibits potent antiproliferative and anticancer activities. Chlamydocin induces apoptosis by activating caspase-3 .
    Chlamydocin
  • HY-100624
    Ryuvidine

    		CDK Cancer
    Ryuvidine is a potent inhibitor of SET domain-containing protein 8(SETD8) with an IC50 of 0.5 µM and suppresses monomethylation of H4K20 in vitro . Ryuvidine also inhibits CDK4 with an IC50 of 6.0 μM and is cytotoxic against a range of human cancer cells .
    Ryuvidine
  • HY-149302
    MC4033

    		Apoptosis Autophagy Histone Acetyltransferase Cancer
    MC4033 shows IC50s of 39.4 μM, 52.1 μM, 41 μM and 30.1 μM in HCT116, H1299, A549 and U937, respectively .
    MC4033 (25, 50, 100, and 200 μM, 72 h) reduces the level of H4K16Ac in HT29 cells, suggesting its ability to inhibit KAT8 in cells .
    MC4033
  • HY-117709
    BRD6688

    		HDAC Neurological Disease
    BRD6688 is a selective HDAC2 inhibitor. BRD6688 increases H4K12 and H3K9 histone acetylation in primary mouse neuronal cells. BRD6688 crosses the blood brain barrier and rescues the memory defects associated with p25 induced neurodegeneration in contextual fear conditioning in a CK-p25 mouse model .
    BRD6688
  • HY-120137
    CMP-5

    		Histone Methyltransferase Cancer
    CMP-5 is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation but leaving normal B cells unaffected .
    CMP-5
  • HY-113846
    CMP-5 hydrochloride

    		Histone Methyltransferase Cancer
    CMP-5 hydrochloride is a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 hydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 hydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected .
    CMP-5 hydrochloride
  • HY-N0930B
    Galegine hydrochloride

    		AMPK Bacterial Infection Metabolic Disease
    Galegine hydrochloride, a guanidine derivative, contributes to weight loss in mice. Guanidine hydrochloride is the compound derived from G. officinalis, which gave rise to the biguanides, metformin and phenformin. Galegine hydrochloride activates AMPK in 3T3-L1 adipocytes and L6 myotubes, as well as in the H4IIE rat hepatoma and HEK293 human kidney cell lines. Galegine hydrochloride has antibacterial activity, with minimum inhibitory concentration of 4 mg/L against Staphylococcus aureus strains .
    Galegine hydrochloride
  • HY-156096
    HDAC3-IN-2

    		HDAC Histone Methyltransferase Caspase Apoptosis DNA/RNA Synthesis Cancer
    HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC50: 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC50 of 0.55 μM against 4T1 and an IC50 of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels .
    HDAC3-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: